Medicare Spends Billions on Oncology Drugs Offering Little Added Benefit

[ad_1]

(MedPage Today) — In an analysis of Medicare’s top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no added benefit.
In 2022, Medicare…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114981

Author :

Publish date : 2025-04-04 21:02:00

Copyright for syndicated content belongs to the linked Source.